Page 21 - Toddler Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ News provided by Share this article Share this article SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche. Approval for Evrysdi from the European Medicines Agency was received on March 30 for the treatment of spinal muscular atrophy (SMA) in adult...

Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients - Sustained or improved motor function was observed with 24 months of treatment - - Patients and caregivers reported a greater ability to complete activities of daily livingwith increased independence - News provided by Share this article Share this article SOUTH PLAINFIELD, N.J., March 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam...

Has he spent time away from you? If your child has been cared for by a babysitter or a relative, he'll be better prepared to separate from you when he's at preschool. Kids who are used to being apart from their parents often bounce right into preschool with hardly a backward glance. If your child hasn't had many opportunities to be away from you, you might want to schedule some – a weekend with grandma, for instance, or a day with your sister and her kids. But even if you can't work out your separation issues up front, don't worry too much. Many children leave Mom or Dad for the first time...

SOUTH PLAINFIELD, N.J., Feb. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. , today announced that the European Medicines Agency Committee for Medicinal Products for Human Use has recommended the... | March 4, 2021

F. Hoffmann-La Roche Ltd: Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older More than 2,500 patients now treated with Evrysdi in clinical trial, compassionate use and real-world settings Evrysdi is approved in seven countries, submitted in 30 more Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrys...